Business Context and Reporting Period
Company: Context Therapeutics Inc. (CNTX)
Reporting Period: Quarter ended June 30, 2025 (Q2 2025)
Business Overview: Context Therapeutics is a clinical-stage biopharmaceutical company developing T cell engaging (TCE) bispecific antibodies for solid tumors. The company has no product revenue and is focused on advancing three primary candidates: CTIM-76 (CLDN6 x CD3), CT-95 (MSLN x CD3), and CT-202 (Nectin-4 x CD3). The company is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(8.83) million | $(2.25) million | $(13.40) million | $(5.92) million |
| Loss Per Share (Basic/Diluted) | $(0.09) | $(0.04) | $(0.14) | $(0.17) |
| Research & Development Expenses | $7.83 million | $1.38 million | $11.29 million | $3.36 million |
| General & Administrative Expenses | $1.93 million | $1.70 million | $3.99 million | $3.55 million |
| Cash and Cash Equivalents (End of Period) | $83.52 million | $101.54 million | $83.52 million | $101.54 million |
| Cash Used in Operating Activities (YTD) | $(10.86) million | $(7.72) million | $(10.86) million | $(7.72) million |
| Accumulated Deficit | $(108.18) million | $(73.98) million | $(108.18) million | $(73.98) million |
Material Changes vs. Prior Period
- Significant Increase in R&D Spend: Research and development expenses increased by 466% ($6.45 million) in Q2 2025 compared to Q2 2024. This surge is driven by the initiation of Phase 1 clinical trials for CTIM-76 (first patient dosed Jan 2025) and CT-95 (first patient dosed April 2025), as well as preclinical and manufacturing costs for the newly acquired CT-202.
- Net Loss Expansion: Net loss widened to $8.83 million in Q2 2025 from $2.25 million in the prior year quarter, primarily due to the increased operational scale and clinical trial activities.
- Interest Income Growth: Interest income rose to $0.90 million in Q2 2025 from $0.84 million in Q2 2024, reflecting higher cash balances resulting from the May 2024 private placement and December 2024 ATM offering.
- Share Count Stability: The weighted average shares outstanding increased significantly year-over-year (95.2 million vs. 55.0 million) due to the May 2024 private placement, though the share count remained stable between Q1 and Q2 2025.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes cash of $83.5 million as of June 30, 2025, is sufficient to fund operations into 2027. This runway covers the dose escalation portions of CTIM-76 and CT-95 Phase 1 trials and the initiation of the CT-202 first-in-human trial.
- Clinical Milestones:
- CTIM-76: Initial dose escalation data expected in Q2 2026.
- CT-95: Initial dose escalation data expected in mid-2026.
- CT-202: Regulatory filings for first-in-human trial expected in Q2 2026.
- Capital Needs: The company anticipates needing substantial additional capital to continue operations and commercialize products. Future funding may come from equity offerings, debt, or collaborations. Failure to secure funding could force delays or curtailment of operations.
- Risk Factors:
- Regulatory Uncertainty: Potential disruptions to FDA approval processes due to changes in U.S. federal regulatory agencies and workforce reductions.
- Trade Policy: Risks associated with U.S. trade policy changes and tariffs affecting the cost of raw materials and clinical supplies.
- Intellectual Property: Potential third-party patent claims regarding CTIM-76, though the company believes it has reasonable defenses.
Investor Verification Checklist
- Cash Runway Validation: Verify if the $83.5 million cash balance is sufficient to reach the stated 2027 milestone given the current burn rate of ~$11 million per six months.
- Clinical Trial Progress: Monitor the initiation and enrollment rates of the Phase 1 trials for CTIM-76 and CT-95, and the regulatory filing status for CT-202.
- Financing Plans: Assess the company's ability to raise additional capital through its At-The-Market (ATM) facility or new private placements without excessive dilution.
- R&D Cost Allocation: Review the specific cost drivers for the 466% increase in R&D expenses to ensure alignment with clinical milestones.
- Regulatory Environment: Monitor updates on FDA staffing and policy changes that could impact the timeline for IND approvals and clinical trial conduct.